{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:29:02Z","timestamp":1787009342486,"version":"build-2736575974"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>TAFRO syndrome, a rare disease characterised by thrombocytopaenia, anasarca, fever, reticulin fibrosis, and organomegaly, is thought to be caused by hypercytokinaemia. It is a heterogeneous clinical entity, and a recent comprehensive international definition defined TAFRO syndrome with lymph node histopathology consistent with idiopathic multicentric Castleman disease (iMCD) as iMCD-TAFRO. Herein, we present a rare case of iMCD-TAFRO following coronavirus disease 2019 (COVID-19) infection. A 62-year-old Japanese woman, initially diagnosed with COVID-19, developed a persistent fever and fluid retention, prompting the diagnosis of iMCD-TAFRO. Following the initiation of prednisolone and cyclosporine, her symptoms gradually resolved. Therefore, we discuss the potential pathophysiological link between COVID-19 and iMCD-TAFRO, emphasising the role of cytokine storms. This case report highlights the importance of recognising the spectrum of inflammatory states after COVID-19 and differentiating iMCD-TAFRO after COVID-19 from the COVID-19 cytokine storm syndrome.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae045","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T18:50:04Z","timestamp":1723661404000},"page":"174-178","source":"Crossref","is-referenced-by-count":1,"title":["Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report"],"prefix":"10.1093","volume":"9","author":[{"given":"Tatsuro","family":"Shiina","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko Kashihara","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sendo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-2011","authenticated-orcid":false,"given":"Maki","family":"Kanzawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kobe University Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-3743","authenticated-orcid":false,"given":"Jun","family":"Saegusa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"2025011615470858700_R1","first-page":"320","article-title":"Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites, and hepatosplenomegaly","volume":"51","author":"Takai","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"2025011615470858700_R2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki","year":"2016","journal-title":"Int J Hematol"},{"key":"2025011615470858700_R3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated International Definition of the TAFRO clinical subtype of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"key":"2025011615470858700_R4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"2025011615470858700_R5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.26456","article-title":"Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review","volume":"4","author":"Patel","year":"2021","journal-title":"JAMA Network Open"},{"key":"2025011615470858700_R6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/22221751.2021.1884503","article-title":"COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue","volume":"10","author":"Yongzhi","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"2025011615470858700_R7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00277-022-04762-6","article-title":"Castleman disease and TAFRO syndrome","volume":"101","author":"Masaki","year":"2022","journal-title":"Ann Hematol"},{"key":"2025011615470858700_R8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"2025011615470858700_R9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3960\/jslrt.53.87","article-title":"Atypical hyaline vascular-type castleman\u2019s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy","volume":"53","author":"Iwaki","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"2025011615470858700_R10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome","volume":"111","author":"Masaki","year":"2020","journal-title":"Int J Hematol"},{"key":"2025011615470858700_R11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2020-218323","article-title":"Preliminary predictive criteria for COVID-19 cytokine storm","volume":"80","author":"Caricchio","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025011615470858700_R12","article-title":"Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Adults (MIS-A). Atlanta, GA: United States Department of Health and Human Services, Centers for Disease Control and Prevention (US)","author":"CDC","year":"2023"},{"key":"2025011615470858700_R13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12185-023-03589-9","article-title":"Severe systemic inflammation mimicking TAFRO syndrome following COVID-19","volume":"118","author":"Tane","year":"2023","journal-title":"Int J Hematol"},{"key":"2025011615470858700_R14","article-title":"A case of TAFRO syndrome developed after COVID-19 vaccination","volume":"2023","author":"Hirose","year":"2023","journal-title":"Case Rep Nephrol"},{"key":"2025011615470858700_R15","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jiac.2022.04.005","article-title":"TAFRO syndrome with a fetal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: a case report","volume":"28","author":"Yamada","year":"2022","journal-title":"J Infect Chemother"},{"key":"2025011615470858700_R16","article-title":"Severe coronavirus disease 2019 in a patient with TAFRO syndrome: a case report","volume":"16","author":"Oshima","year":"2022","journal-title":"Clin Infect Pract"},{"key":"2025011615470858700_R17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ccr3.284","article-title":"Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome","volume":"3","author":"Tatekawa","year":"2015","journal-title":"Clin Case Rep"},{"key":"2025011615470858700_R18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1620\/tjem.236.289","article-title":"Successful treatment of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, with cyclosporine A: possible pathogenetic contribution of interleukin-2","volume":"236","author":"Konishi","year":"2015","journal-title":"Tohoku J Exp Med"},{"key":"2025011615470858700_R19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/14397595.2016.1206243","article-title":"A case of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, successfully treated with corticosteroid and cyclosporine A","volume":"29","author":"Takasawa","year":"2019","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae045\/58977262\/rxae045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/1\/174\/58977262\/rxae045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/1\/174\/58977262\/rxae045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:53:53Z","timestamp":1737024833000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/9\/1\/174\/7739789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,23]]},"published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae045","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,23]]}}}